{
  "DOI": "10.1186/s40246-023-00511-6",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00511-6",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eFemale breast cancer remains the second leading cause of cancer-related death in the USA. The heterogeneity in the tumor morphology across the cohort and within patients can lead to unpredictable therapy resistance, metastasis, and clinical outcome. Hence, supplementing classic pathological markers with intrinsic tumor molecular markers can help identify novel molecular subtypes and the discovery of actionable biomarkers.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eMethods\u003c/jats:title\u003e\n                \u003cjats:p\u003eWe conducted a large multi-institutional genomic analysis of paired normal and tumor samples from breast cancer patients to profile the complex genomic architecture of breast tumors. Long-term patient follow-up, therapeutic regimens, and treatment response for this cohort are documented using the Breast Cancer Collaborative Registry. The majority of the patients in this study were at tumor stage 1 (51.4%) and stage 2 (36.3%) at the time of diagnosis. Whole-exome sequencing data from 554 patients were used for mutational profiling and identifying cancer drivers.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eWe identified 54 tumors having at least 1000 mutations and 185 tumors with less than 100 mutations. Tumor mutational burden varied across the classified subtypes, and the top ten mutated genes include \u003cjats:italic\u003eMUC4, MUC16, PIK3CA, TTN, TP53, NBPF10, NBPF1, CDC27, AHNAK2\u003c/jats:italic\u003e, and \u003cjats:italic\u003eMUC2\u003c/jats:italic\u003e. Patients were classified based on seven biological and tumor-specific parameters, including grade, stage, hormone receptor status, histological subtype, Ki67 expression, lymph node status, race, and mutational profiles compared across different subtypes. Mutual exclusion of mutations in \u003cjats:italic\u003ePIK3CA\u003c/jats:italic\u003e and \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e was pronounced across different tumor grades. Cancer drivers specific to each subtype include \u003cjats:italic\u003eTP53, PIK3CA, CDC27, CDH1, STK39, CBFB, MAP3K1\u003c/jats:italic\u003e, and \u003cjats:italic\u003eGATA3\u003c/jats:italic\u003e, and mutations associated with patient survival were identified in our cohort.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusions\u003c/jats:title\u003e\n                \u003cjats:p\u003eThis extensive study has revealed tumor burden, driver genes, co-occurrence, mutual exclusivity, and survival effects of mutations on a US Midwestern breast cancer cohort, paving the way for developing personalized therapeutic strategies.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "511"
  ],
  "article-number": "64",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "31 December 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "11 July 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "15 July 2023"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "This study was approved by the Institutional Review Board (IRB) of the University of Nebraska Medical Center (0155-13-EP, and the IRB for the data collection (iCaRe2) is 253-13-EP). Patients gave their informed written consent to participate in this study."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Competing of interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors have no conflicts of interest to declare."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Vellichirammal",
      "given": "Neetha Nanoth",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Tan",
      "given": "Yuan-De",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Xiao",
      "given": "Peng",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Eudy",
      "given": "James",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Shats",
      "given": "Oleg",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Kelly",
      "given": "David",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Desler",
      "given": "Michelle",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cowan",
      "given": "Kenneth",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Guda",
      "given": "Chittibabu",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        7,
        15
      ]
    ],
    "date-time": "2023-07-15T10:02:29Z",
    "timestamp": 1689415349000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        7,
        15
      ]
    ],
    "date-time": "2023-07-15T10:04:22Z",
    "timestamp": 1689415462000
  },
  "funder": [
    {
      "award": [
        "5P30CA036727"
      ],
      "name": "NIH"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2023,
        7,
        16
      ]
    ],
    "date-time": "2023-07-16T04:14:03Z",
    "timestamp": 1689480843265
  },
  "is-referenced-by-count": 0,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2023,
        7,
        15
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2023,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            7,
            15
          ]
        ],
        "date-time": "2023-07-15T00:00:00Z",
        "timestamp": 1689379200000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            7,
            15
          ]
        ],
        "date-time": "2023-07-15T00:00:00Z",
        "timestamp": 1689379200000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00511-6.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00511-6/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00511-6.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2023,
        7,
        15
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        7,
        15
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1002/cncr.32648",
      "author": "AM Afifi",
      "doi-asserted-by": "publisher",
      "first-page": "1559",
      "issue": "7",
      "journal-title": "Cancer",
      "key": "511_CR1",
      "unstructured": "Afifi AM, Saad AM, Al-Husseini MJ, Elmehrath AO, Northfelt DW, Sonbol MB. Causes of death after breast cancer diagnosis: a US population-based analysis. Cancer. 2020;126(7):1559–67.",
      "volume": "126",
      "year": "2020"
    },
    {
      "DOI": "10.1002/ijc.33588",
      "author": "J Ferlay",
      "doi-asserted-by": "publisher",
      "first-page": "778",
      "journal-title": "Int J Cancer",
      "key": "511_CR2",
      "unstructured": "Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778.",
      "volume": "149",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.cell.2011.02.013",
      "author": "D Hanahan",
      "doi-asserted-by": "publisher",
      "first-page": "646",
      "issue": "5",
      "journal-title": "Cell",
      "key": "511_CR3",
      "unstructured": "Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.",
      "volume": "144",
      "year": "2011"
    },
    {
      "DOI": "10.1007/s13244-012-0196-6",
      "author": "F Davnall",
      "doi-asserted-by": "publisher",
      "first-page": "573",
      "issue": "6",
      "journal-title": "Insights Imaging",
      "key": "511_CR4",
      "unstructured": "Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, Ganeshan B, Miles KA, Cook GJ, Goh V. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3(6):573–89.",
      "volume": "3",
      "year": "2012"
    },
    {
      "DOI": "10.1038/nature12627",
      "author": "PL Bedard",
      "doi-asserted-by": "publisher",
      "first-page": "355",
      "issue": "7467",
      "journal-title": "Nature",
      "key": "511_CR5",
      "unstructured": "Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–64.",
      "volume": "501",
      "year": "2013"
    },
    {
      "DOI": "10.1186/s12885-021-07931-4",
      "author": "CC Huang",
      "doi-asserted-by": "publisher",
      "first-page": "199",
      "issue": "1",
      "journal-title": "BMC Cancer",
      "key": "511_CR6",
      "unstructured": "Huang CC, Tsai YF, Liu CY, Chao TC, Lien PJ, Lin YS, Feng CJ, Chiu JH, Hsu CY, Tseng LM. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses. BMC Cancer. 2021;21(1):199.",
      "volume": "21",
      "year": "2021"
    },
    {
      "DOI": "10.1038/nature10983",
      "author": "C Curtis",
      "doi-asserted-by": "publisher",
      "first-page": "346",
      "issue": "7403",
      "journal-title": "Nature",
      "key": "511_CR7",
      "unstructured": "Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.",
      "volume": "486",
      "year": "2012"
    },
    {
      "DOI": "10.1038/nature11154",
      "author": "S Banerji",
      "doi-asserted-by": "publisher",
      "first-page": "405",
      "issue": "7403",
      "journal-title": "Nature",
      "key": "511_CR8",
      "unstructured": "Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–9.",
      "volume": "486",
      "year": "2012"
    },
    {
      "DOI": "10.1016/S0140-6736(11)61539-0",
      "author": "JS Reis-Filho",
      "doi-asserted-by": "publisher",
      "first-page": "1812",
      "issue": "9805",
      "journal-title": "Lancet",
      "key": "511_CR9",
      "unstructured": "Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–23.",
      "volume": "378",
      "year": "2011"
    },
    {
      "DOI": "10.1200/JCO.2004.05.166",
      "author": "M Ayers",
      "doi-asserted-by": "publisher",
      "first-page": "2284",
      "issue": "12",
      "journal-title": "J Clin Oncol",
      "key": "511_CR10",
      "unstructured": "Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004;22(12):2284–93.",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1200/JCO.2006.05.6861",
      "author": "KR Hess",
      "doi-asserted-by": "publisher",
      "first-page": "4236",
      "issue": "26",
      "journal-title": "J Clin Oncol",
      "key": "511_CR11",
      "unstructured": "Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24(26):4236–44.",
      "volume": "24",
      "year": "2006"
    },
    {
      "DOI": "10.1002/path.2648",
      "author": "B Weigelt",
      "doi-asserted-by": "publisher",
      "first-page": "263",
      "issue": "2",
      "journal-title": "J Pathol",
      "key": "511_CR12",
      "unstructured": "Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;220(2):263–80.",
      "volume": "220",
      "year": "2010"
    },
    {
      "DOI": "10.1186/s13058-017-0812-y",
      "author": "MR Aure",
      "doi-asserted-by": "publisher",
      "first-page": "44",
      "issue": "1",
      "journal-title": "Breast Cancer Res",
      "key": "511_CR13",
      "unstructured": "Aure MR, Vitelli V, Jernstrom S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Luders T, et al. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Res. 2017;19(1):44.",
      "volume": "19",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s10549-016-3826-8",
      "author": "X Chen",
      "doi-asserted-by": "publisher",
      "first-page": "267",
      "issue": "2",
      "journal-title": "Breast Cancer Res Treat",
      "key": "511_CR14",
      "unstructured": "Chen X, Hu H, He L, Yu X, Liu X, Zhong R, Shu M. A novel subtype classification and risk of breast cancer by histone modification profiling. Breast Cancer Res Treat. 2016;157(2):267–79.",
      "volume": "157",
      "year": "2016"
    },
    {
      "DOI": "10.1093/hmg/ddu733",
      "author": "C Dong",
      "doi-asserted-by": "publisher",
      "first-page": "2125",
      "issue": "8",
      "journal-title": "Hum Mol Genet",
      "key": "511_CR15",
      "unstructured": "Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24(8):2125–37.",
      "volume": "24",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.molonc.2010.11.003",
      "author": "A Prat",
      "doi-asserted-by": "publisher",
      "first-page": "5",
      "issue": "1",
      "journal-title": "Mol Oncol",
      "key": "511_CR16",
      "unstructured": "Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5–23.",
      "volume": "5",
      "year": "2011"
    },
    {
      "DOI": "10.1186/bcr2635",
      "author": "A Prat",
      "doi-asserted-by": "publisher",
      "first-page": "R68",
      "issue": "5",
      "journal-title": "Breast Cancer Res",
      "key": "511_CR17",
      "unstructured": "Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.",
      "volume": "12",
      "year": "2010"
    },
    {
      "DOI": "10.1038/s41523-021-00278-w",
      "author": "R Luo",
      "doi-asserted-by": "publisher",
      "first-page": "72",
      "issue": "1",
      "journal-title": "NPJ Breast Cancer",
      "key": "511_CR18",
      "unstructured": "Luo R, Chong W, Wei Q, Zhang Z, Wang C, Ye Z, Abu-Khalaf MM, Silver DP, Stapp RT, Jiang W, et al. Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. NPJ Breast Cancer. 2021;7(1):72.",
      "volume": "7",
      "year": "2021"
    },
    {
      "DOI": "10.3727/096504019X15698362825407",
      "author": "YS Chang",
      "doi-asserted-by": "publisher",
      "first-page": "107",
      "issue": "2",
      "journal-title": "Oncol Res",
      "key": "511_CR19",
      "unstructured": "Chang YS, Chang CM, Lin CY, Chao DS, Huang HY, Chang JG. Pathway mutations in breast cancer using whole-exome sequencing. Oncol Res. 2020;28(2):107–16.",
      "volume": "28",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.ctrv.2017.10.012",
      "author": "EJ Blok",
      "doi-asserted-by": "publisher",
      "first-page": "74",
      "journal-title": "Cancer Treat Rev",
      "key": "511_CR20",
      "unstructured": "Blok EJ, Bastiaannet E, van den Hout WB, Liefers GJ, Smit V, Kroep JR, van de Velde CJH. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev. 2018;62:74–90.",
      "volume": "62",
      "year": "2018"
    },
    {
      "DOI": "10.1038/s41416-020-01247-z",
      "author": "P Giorgi Rossi",
      "doi-asserted-by": "publisher",
      "first-page": "1503",
      "issue": "9",
      "journal-title": "Br J Cancer",
      "key": "511_CR21",
      "unstructured": "Giorgi Rossi P, Lebeau A, Canelo-Aybar C, Saz-Parkinson Z, Quinn C, Langendam M, McGarrigle H, Warman S, Rigau D, Alonso-Coello P, et al. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. Br J Cancer. 2021;124(9):1503–12.",
      "volume": "124",
      "year": "2021"
    },
    {
      "author": "S Sherman",
      "first-page": "217",
      "journal-title": "Cancer Inform",
      "key": "511_CR22",
      "unstructured": "Sherman S, Shats O, Fleissner E, Bascom G, Yiee K, Copur M, Crow K, Rooney J, Mateen Z, Ketcham MA, et al. Multicenter breast cancer collaborative registry. Cancer Inform. 2011;10:217–26.",
      "volume": "10",
      "year": "2011"
    },
    {
      "DOI": "10.1158/1535-7163.MCT-17-0386",
      "author": "AM Goodman",
      "doi-asserted-by": "publisher",
      "first-page": "2598",
      "issue": "11",
      "journal-title": "Mol Cancer Ther",
      "key": "511_CR23",
      "unstructured": "Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–608.",
      "volume": "16",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.2017.75.3384",
      "author": "H Rizvi",
      "doi-asserted-by": "publisher",
      "first-page": "633",
      "issue": "7",
      "journal-title": "J Clin Oncol",
      "key": "511_CR24",
      "unstructured": "Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–41.",
      "volume": "36",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.2021.39.15_suppl.1091",
      "author": "S Sammons",
      "doi-asserted-by": "publisher",
      "first-page": "1091",
      "issue": "15_suppl",
      "journal-title": "J Clin Oncol",
      "key": "511_CR25",
      "unstructured": "Sammons S, Elliott A, Force JM, DeVito NC, Marcom PK, Swain SM, Tan AR, Torres ETR, Zeng J, Khasraw M, et al. Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features. J Clin Oncol. 2021;39(15_suppl):1091–1091.",
      "volume": "39",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41568-019-0179-8",
      "author": "F Skoulidis",
      "doi-asserted-by": "publisher",
      "first-page": "495",
      "issue": "9",
      "journal-title": "Nat Rev Cancer",
      "key": "511_CR26",
      "unstructured": "Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495–509.",
      "volume": "19",
      "year": "2019"
    },
    {
      "DOI": "10.1200/JCO.2017.74.8301",
      "author": "D Zardavas",
      "doi-asserted-by": "publisher",
      "first-page": "981",
      "issue": "10",
      "journal-title": "J Clin Oncol",
      "key": "511_CR27",
      "unstructured": "Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol. 2018;36(10):981–90.",
      "volume": "36",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.2013.53.8272",
      "author": "VS Sabine",
      "doi-asserted-by": "publisher",
      "first-page": "2951",
      "issue": "27",
      "journal-title": "J Clin Oncol",
      "key": "511_CR28",
      "unstructured": "Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol. 2014;32(27):2951–8.",
      "volume": "32",
      "year": "2014"
    },
    {
      "DOI": "10.1371/journal.pone.0140293",
      "author": "G Papaxoinis",
      "doi-asserted-by": "publisher",
      "first-page": "e0140293",
      "issue": "10",
      "journal-title": "PLoS ONE",
      "key": "511_CR29",
      "unstructured": "Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, et al. Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: a hellenic cooperative oncology Group (HeCOG) study. PLoS ONE. 2015;10(10):e0140293.",
      "volume": "10",
      "year": "2015"
    },
    {
      "DOI": "10.1371/journal.pone.0036924",
      "author": "A Tikoo",
      "doi-asserted-by": "publisher",
      "first-page": "e36924",
      "issue": "5",
      "journal-title": "PLoS ONE",
      "key": "511_CR30",
      "unstructured": "Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERalpha-positive tumors. PLoS ONE. 2012;7(5):e36924.",
      "volume": "7",
      "year": "2012"
    },
    {
      "DOI": "10.1073/pnas.0907011107",
      "author": "S Loi",
      "doi-asserted-by": "publisher",
      "first-page": "10208",
      "issue": "22",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "511_CR31",
      "unstructured": "Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010;107(22):10208–13.",
      "volume": "107",
      "year": "2010"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-05-1029",
      "author": "M Olivier",
      "doi-asserted-by": "publisher",
      "first-page": "1157",
      "issue": "4",
      "journal-title": "Clin Cancer Res",
      "key": "511_CR32",
      "unstructured": "Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12(4):1157–67.",
      "volume": "12",
      "year": "2006"
    },
    {
      "author": "B Powell",
      "first-page": "443",
      "issue": "2",
      "journal-title": "Clin Cancer Res",
      "key": "511_CR33",
      "unstructured": "Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res. 2000;6(2):443–51.",
      "volume": "6",
      "year": "2000"
    },
    {
      "DOI": "10.1111/1759-7714.13467",
      "author": "X Li",
      "doi-asserted-by": "publisher",
      "first-page": "1861",
      "issue": "7",
      "journal-title": "Thorac Cancer",
      "key": "511_CR34",
      "unstructured": "Li X, Chen X, Wen L, Wang Y, Chen B, Xue Y, Guo L, Liao N. Impact of TP53 mutations in breast cancer: clinicopathological features and prognosisImpact of TP53 mutations in breast CA. Thorac Cancer. 2020;11(7):1861–8.",
      "volume": "11",
      "year": "2020"
    },
    {
      "DOI": "10.1038/ncb1530",
      "author": "ML Asselin-Labat",
      "doi-asserted-by": "publisher",
      "first-page": "201",
      "issue": "2",
      "journal-title": "Nat Cell Biol",
      "key": "511_CR35",
      "unstructured": "Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007;9(2):201–9.",
      "volume": "9",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.ccr.2008.01.011",
      "author": "H Kouros-Mehr",
      "doi-asserted-by": "publisher",
      "first-page": "141",
      "issue": "2",
      "journal-title": "Cancer Cell",
      "key": "511_CR36",
      "unstructured": "Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. 2008;13(2):141–52.",
      "volume": "13",
      "year": "2008"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-05-2495",
      "author": "R Mehra",
      "doi-asserted-by": "publisher",
      "first-page": "11259",
      "issue": "24",
      "journal-title": "Cancer Res",
      "key": "511_CR37",
      "unstructured": "Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005;65(24):11259–64.",
      "volume": "65",
      "year": "2005"
    },
    {
      "DOI": "10.1016/j.jamcollsurg.2004.12.025",
      "author": "P Parikh",
      "doi-asserted-by": "publisher",
      "first-page": "705",
      "issue": "5",
      "journal-title": "J Am Coll Surg",
      "key": "511_CR38",
      "unstructured": "Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg. 2005;200(5):705–10.",
      "volume": "200",
      "year": "2005"
    },
    {
      "DOI": "10.3727/105221615X14399878166113",
      "author": "M Takaku",
      "doi-asserted-by": "publisher",
      "first-page": "163",
      "issue": "4",
      "journal-title": "Gene Expr",
      "key": "511_CR39",
      "unstructured": "Takaku M, Grimm SA, Wade PA. GATA3 in breast cancer: tumor suppressor or oncogene? Gene Expr. 2015;16(4):163–8.",
      "volume": "16",
      "year": "2015"
    },
    {
      "DOI": "10.1093/nar/gkaa179",
      "author": "M Takaku",
      "doi-asserted-by": "publisher",
      "first-page": "4756",
      "issue": "9",
      "journal-title": "Nucleic Acids Res",
      "key": "511_CR40",
      "unstructured": "Takaku M, Grimm SA, De Kumar B, Bennett BD, Wade PA. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3. Nucleic Acids Res. 2020;48(9):4756–68.",
      "volume": "48",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10549-005-9009-7",
      "author": "S Cleator",
      "doi-asserted-by": "publisher",
      "first-page": "229",
      "issue": "3",
      "journal-title": "Breast Cancer Res Treat",
      "key": "511_CR41",
      "unstructured": "Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O’Connell P, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006;95(3):229–33.",
      "volume": "95",
      "year": "2006"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-05-3082",
      "author": "PJ Hendriksen",
      "doi-asserted-by": "publisher",
      "first-page": "5012",
      "issue": "10",
      "journal-title": "Cancer Res",
      "key": "511_CR42",
      "unstructured": "Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006;66(10):5012–20.",
      "volume": "66",
      "year": "2006"
    },
    {
      "DOI": "10.18632/oncotarget.11351",
      "author": "Z Li",
      "doi-asserted-by": "publisher",
      "first-page": "61366",
      "issue": "38",
      "journal-title": "Oncotarget",
      "key": "511_CR43",
      "unstructured": "Li Z, Zhu W, Xiong L, Yu X, Chen X, Lin Q. Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells. Oncotarget. 2016;7(38):61366–77.",
      "volume": "7",
      "year": "2016"
    },
    {
      "DOI": "10.3892/ol.2017.6728",
      "author": "T Huang",
      "doi-asserted-by": "publisher",
      "first-page": "4599",
      "issue": "4",
      "journal-title": "Oncol Lett",
      "key": "511_CR44",
      "unstructured": "Huang T, Zhou Y, Cao Y, Tao J, Zhou ZH, Hang DH. STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation. Oncol Lett. 2017;14(4):4599–604.",
      "volume": "14",
      "year": "2017"
    },
    {
      "DOI": "10.2147/OTT.S153806",
      "author": "Q Zhao",
      "doi-asserted-by": "publisher",
      "first-page": "1511",
      "journal-title": "Onco Targets Ther",
      "key": "511_CR45",
      "unstructured": "Zhao Q, Zhu Y, Liu L, Wang H, Jiang S, Hu X, Guo J. STK39 blockage by RNA interference inhibits the proliferation and induces the apoptosis of renal cell carcinoma. Onco Targets Ther. 2018;11:1511–9.",
      "volume": "11",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.vaccine.2019.05.024",
      "author": "SE Stanton",
      "doi-asserted-by": "publisher",
      "first-page": "3552",
      "issue": "27",
      "journal-title": "Vaccine",
      "key": "511_CR46",
      "unstructured": "Stanton SE, Gad E, Corulli LR, Lu H, Disis ML. Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets. Vaccine. 2019;37(27):3552–61.",
      "volume": "37",
      "year": "2019"
    },
    {
      "author": "C Li",
      "first-page": "1221",
      "issue": "4",
      "journal-title": "Oncol Rep",
      "key": "511_CR47",
      "unstructured": "Li C, Wang A, Chen Y, Liu Y, Zhang H, Zhou J. MicroRNA2995p inhibits cell metastasis in breast cancer by directly targeting serine/threonine kinase 39. Oncol Rep. 2020;43(4):1221–33.",
      "volume": "43",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41467-019-10102-6",
      "author": "N Malik",
      "doi-asserted-by": "publisher",
      "first-page": "2071",
      "issue": "1",
      "journal-title": "Nat Commun",
      "key": "511_CR48",
      "unstructured": "Malik N, Yan H, Moshkovich N, Palangat M, Yang H, Sanchez V, Cai Z, Peat TJ, Jiang S, Liu C, et al. The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription. Nat Commun. 2019;10(1):2071.",
      "volume": "10",
      "year": "2019"
    },
    {
      "DOI": "10.1158/1541-7786.MCR-18-1039",
      "author": "HJ Pegg",
      "doi-asserted-by": "publisher",
      "first-page": "1015",
      "issue": "5",
      "journal-title": "Mol Cancer Res",
      "key": "511_CR49",
      "unstructured": "Pegg HJ, Harrison H, Rogerson C, Shore P. The RUNX transcriptional coregulator, CBFbeta, suppresses migration of ER(+) Breast cancer cells by repressing ERalpha-mediated expression of the migratory factor TFF1. Mol Cancer Res. 2019;17(5):1015–23.",
      "volume": "17",
      "year": "2019"
    },
    {
      "DOI": "10.1371/journal.pgen.1009553",
      "author": "N Malik",
      "doi-asserted-by": "publisher",
      "first-page": "e1009553",
      "issue": "5",
      "journal-title": "PLoS Genet",
      "key": "511_CR50",
      "unstructured": "Malik N, Yan H, Yang HH, Ayaz G, DuBois W, Tseng YC, Kim YI, Jiang S, Liu C, Lee M, et al. CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer. PLoS Genet. 2021;17(5):e1009553.",
      "volume": "17",
      "year": "2021"
    },
    {
      "author": "V Andries",
      "key": "511_CR51",
      "unstructured": "Andries V. Functional analysis of the NBPF1 gene in cancer. Thesis: Ghent University; 2012.",
      "volume-title": "Functional analysis of the NBPF1 gene in cancer",
      "year": "2012"
    },
    {
      "DOI": "10.2147/OTT.S281517",
      "author": "G Liu",
      "doi-asserted-by": "publisher",
      "first-page": "12893",
      "journal-title": "Onco Targets Ther",
      "key": "511_CR52",
      "unstructured": "Liu G, Guo Z, Zhang Q, Liu Z, Zhu D. AHNAK2 promotes migration, invasion, and epithelial-mesenchymal transition in lung adenocarcinoma cells via the TGF-beta/Smad3 pathway. Onco Targets Ther. 2020;13:12893–903.",
      "volume": "13",
      "year": "2020"
    },
    {
      "DOI": "10.3727/096504015X14410238486766",
      "author": "Y Qin",
      "doi-asserted-by": "publisher",
      "first-page": "13",
      "issue": "1",
      "journal-title": "Oncol Res",
      "key": "511_CR53",
      "unstructured": "Qin Y, Tang X, Liu M. Tumor-suppressor gene NBPF1 inhibits invasion and PI3K/mTOR signaling in cervical cancer cells. Oncol Res. 2016;23(1):13–20.",
      "volume": "23",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41416-018-0030-0",
      "author": "B Gyorffy",
      "doi-asserted-by": "publisher",
      "first-page": "1107",
      "issue": "8",
      "journal-title": "Br J Cancer",
      "key": "511_CR54",
      "unstructured": "Gyorffy B, Pongor L, Bottai G, Li X, Budczies J, Szabo A, Hatzis C, Pusztai L, Santarpia L. An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. Br J Cancer. 2018;118(8):1107–14.",
      "volume": "118",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.cca.2018.05.030",
      "author": "D Li",
      "doi-asserted-by": "publisher",
      "first-page": "81",
      "journal-title": "Clin Chim Acta",
      "key": "511_CR55",
      "unstructured": "Li D, Li P, Wu J, Yi J, Dou Y, Guo X, Yin Y, Wang D, Ma C, Qiu L. Methylation of NBPF1 as a novel marker for the detection of plasma cell-free DNA of breast cancer patients. Clin Chim Acta. 2018;484:81–6.",
      "volume": "484",
      "year": "2018"
    },
    {
      "DOI": "10.1038/nrc1251",
      "author": "MA Hollingsworth",
      "doi-asserted-by": "publisher",
      "first-page": "45",
      "issue": "1",
      "journal-title": "Nat Rev Cancer",
      "key": "511_CR56",
      "unstructured": "Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45–60.",
      "volume": "4",
      "year": "2004"
    },
    {
      "DOI": "10.1371/journal.pone.0046699",
      "author": "H Valque",
      "doi-asserted-by": "publisher",
      "first-page": "e46699",
      "issue": "10",
      "journal-title": "PLoS ONE",
      "key": "511_CR57",
      "unstructured": "Valque H, Gouyer V, Gottrand F, Desseyn JL. MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS ONE. 2012;7(10):e46699.",
      "volume": "7",
      "year": "2012"
    },
    {
      "DOI": "10.1002/ijc.10853",
      "author": "N Berois",
      "doi-asserted-by": "publisher",
      "first-page": "550",
      "issue": "4",
      "journal-title": "Int J Cancer",
      "key": "511_CR58",
      "unstructured": "Berois N, Varangot M, Sonora C, Zarantonelli L, Pressa C, Lavina R, Rodriguez JL, Delgado F, Porchet N, Aubert JP, et al. Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5B mRNA. Int J Cancer. 2003;103(4):550–5.",
      "volume": "103",
      "year": "2003"
    },
    {
      "DOI": "10.3892/ijo.2016.3434",
      "author": "EP Garcia",
      "doi-asserted-by": "publisher",
      "first-page": "2113",
      "issue": "5",
      "journal-title": "Int J Oncol",
      "key": "511_CR59",
      "unstructured": "Garcia EP, Tiscornia I, Libisch G, Trajtenberg F, Bollati-Fogolin M, Rodriguez E, Noya V, Chiale C, Brossard N, Robello C, et al. MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. Int J Oncol. 2016;48(5):2113–23.",
      "volume": "48",
      "year": "2016"
    },
    {
      "author": "S Yona",
      "first-page": "v",
      "journal-title": "Preface Adv Exp Med Biol",
      "key": "511_CR60",
      "unstructured": "Yona S, Stacey M. Adhesion-GPCRs: structure to function. Preface Adv Exp Med Biol. 2010;706:v–vii.",
      "volume": "706",
      "year": "2010"
    },
    {
      "DOI": "10.1007/978-1-4419-7913-1_9",
      "author": "G Aust",
      "doi-asserted-by": "publisher",
      "first-page": "109",
      "journal-title": "Adv Exp Med Biol",
      "key": "511_CR61",
      "unstructured": "Aust G. Adhesion-GPCRS in tumorigenesis. Adv Exp Med Biol. 2010;706:109–20.",
      "volume": "706",
      "year": "2010"
    },
    {
      "DOI": "10.1007/978-3-319-41523-9_17",
      "author": "G Aust",
      "doi-asserted-by": "publisher",
      "first-page": "369",
      "journal-title": "Handb Exp Pharmacol",
      "key": "511_CR62",
      "unstructured": "Aust G, Zhu D, Van Meir EG, Xu L. Adhesion GPCRs in tumorigenesis. Handb Exp Pharmacol. 2016;234:369–96.",
      "volume": "234",
      "year": "2016"
    },
    {
      "DOI": "10.1371/journal.pbio.3000434",
      "author": "K Sriram",
      "doi-asserted-by": "publisher",
      "first-page": "e3000434",
      "issue": "11",
      "journal-title": "PLoS Biol",
      "key": "511_CR63",
      "unstructured": "Sriram K, Moyung K, Corriden R, Carter H, Insel PA. GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLoS Biol. 2019;17(11):e3000434.",
      "volume": "17",
      "year": "2019"
    },
    {
      "DOI": "10.1038/nature17676",
      "author": "S Nik-Zainal",
      "doi-asserted-by": "publisher",
      "first-page": "47",
      "issue": "7605",
      "journal-title": "Nature",
      "key": "511_CR64",
      "unstructured": "Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47–54.",
      "volume": "534",
      "year": "2016"
    },
    {
      "key": "511_CR65",
      "unstructured": "Andrews S: FASTQC. A quality control tool for high throughput sequence data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. 2010."
    },
    {
      "DOI": "10.1093/bioinformatics/btp698",
      "author": "H Li",
      "doi-asserted-by": "publisher",
      "first-page": "589",
      "issue": "5",
      "journal-title": "Bioinformatics",
      "key": "511_CR66",
      "unstructured": "Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589–95.",
      "volume": "26",
      "year": "2010"
    },
    {
      "DOI": "10.1101/gr.107524.110",
      "author": "A McKenna",
      "doi-asserted-by": "publisher",
      "first-page": "1297",
      "issue": "9",
      "journal-title": "Genome Res",
      "key": "511_CR67",
      "unstructured": "McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.",
      "volume": "20",
      "year": "2010"
    },
    {
      "DOI": "10.1038/ng.806",
      "author": "MA DePristo",
      "doi-asserted-by": "publisher",
      "first-page": "491",
      "issue": "5",
      "journal-title": "Nat Genet",
      "key": "511_CR68",
      "unstructured": "DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8.",
      "volume": "43",
      "year": "2011"
    },
    {
      "DOI": "10.1002/0471250953.bi1110s43",
      "author": "GA Van der Auwera",
      "doi-asserted-by": "crossref",
      "first-page": "11",
      "journal-title": "Curr Protoc Bioinform",
      "key": "511_CR69",
      "unstructured": "Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinform. 2013;43:11.",
      "volume": "43",
      "year": "2013"
    },
    {
      "DOI": "10.1038/nbt.2514",
      "author": "K Cibulskis",
      "doi-asserted-by": "publisher",
      "first-page": "213",
      "issue": "3",
      "journal-title": "Nat Biotechnol",
      "key": "511_CR70",
      "unstructured": "Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9.",
      "volume": "31",
      "year": "2013"
    },
    {
      "key": "511_CR71",
      "unstructured": "Garrison E, Marth G: Haplotype-based variant detection from short-read sequencing. 2012; http://arxiv.org/abs/1207.3907v2."
    },
    {
      "DOI": "10.1093/nar/gkw227",
      "author": "Z Lai",
      "doi-asserted-by": "publisher",
      "first-page": "e108",
      "issue": "11",
      "journal-title": "Nucleic Acids Res",
      "key": "511_CR72",
      "unstructured": "Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, Johnson J, Dougherty B, Barrett JC, Dry JR. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11):e108.",
      "volume": "44",
      "year": "2016"
    },
    {
      "DOI": "10.1093/bioinformatics/btp373",
      "author": "DC Koboldt",
      "doi-asserted-by": "publisher",
      "first-page": "2283",
      "issue": "17",
      "journal-title": "Bioinformatics",
      "key": "511_CR73",
      "unstructured": "Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock GM, Wilson RK, Ding L. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25(17):2283–5.",
      "volume": "25",
      "year": "2009"
    },
    {
      "DOI": "10.1093/nar/gkq603",
      "author": "K Wang",
      "doi-asserted-by": "publisher",
      "first-page": "e164",
      "issue": "16",
      "journal-title": "Nucleic Acids Res",
      "key": "511_CR74",
      "unstructured": "Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.",
      "volume": "38",
      "year": "2010"
    },
    {
      "DOI": "10.1186/s13059-016-0974-4",
      "author": "W McLaren",
      "doi-asserted-by": "publisher",
      "first-page": "122",
      "issue": "1",
      "journal-title": "Genome Biol",
      "key": "511_CR75",
      "unstructured": "McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122.",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nature12213",
      "author": "MS Lawrence",
      "doi-asserted-by": "publisher",
      "first-page": "214",
      "issue": "7457",
      "journal-title": "Nature",
      "key": "511_CR76",
      "unstructured": "Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8.",
      "volume": "499",
      "year": "2013"
    },
    {
      "DOI": "10.1158/2159-8290.CD-17-0321",
      "author": "MT Chang",
      "doi-asserted-by": "publisher",
      "first-page": "174",
      "issue": "2",
      "journal-title": "Cancer Discov",
      "key": "511_CR77",
      "unstructured": "Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 2018;8(2):174–83.",
      "volume": "8",
      "year": "2018"
    },
    {
      "DOI": "10.1038/s41598-017-11746-4",
      "author": "MF Rogers",
      "doi-asserted-by": "publisher",
      "first-page": "11597",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "511_CR78",
      "unstructured": "Rogers MF, Shihab HA, Gaunt TR, Campbell C. CScape: a tool for predicting oncogenic single-point mutations in the cancer genome. Sci Rep. 2017;7(1):11597.",
      "volume": "7",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.cels.2019.05.005",
      "author": "C Tokheim",
      "doi-asserted-by": "publisher",
      "first-page": "9",
      "issue": "1",
      "journal-title": "Cell Syst",
      "key": "511_CR79",
      "unstructured": "Tokheim C, Karchin R. CHASMplus reveals the scope of somatic missense mutations driving human cancers. Cell Syst. 2019;9(1):9-23 e28.",
      "volume": "9",
      "year": "2019"
    },
    {
      "DOI": "10.1038/s41588-019-0572-y",
      "author": "F Dietlein",
      "doi-asserted-by": "publisher",
      "first-page": "208",
      "issue": "2",
      "journal-title": "Nat Genet",
      "key": "511_CR80",
      "unstructured": "Dietlein F, Weghorn D, Taylor-Weiner A, Richters A, Reardon B, Liu D, Lander ES, Van Allen EM, Sunyaev SR. Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020;52(2):208–18.",
      "volume": "52",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.ajhg.2017.04.015",
      "author": "NT Strande",
      "doi-asserted-by": "publisher",
      "first-page": "895",
      "issue": "6",
      "journal-title": "Am J Hum Genet",
      "key": "511_CR81",
      "unstructured": "Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, Goldstein J, Ghosh R, Seifert BA, Sneddon TP, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. Am J Hum Genet. 2017;100(6):895–906.",
      "volume": "100",
      "year": "2017"
    },
    {
      "DOI": "10.1093/nar/gkv1222",
      "author": "MJ Landrum",
      "doi-asserted-by": "publisher",
      "first-page": "D862",
      "issue": "D1",
      "journal-title": "Nucleic Acids Res",
      "key": "511_CR82",
      "unstructured": "Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862-868.",
      "volume": "44",
      "year": "2016"
    },
    {
      "DOI": "10.1093/bioinformatics/btu273",
      "author": "R Leslie",
      "doi-asserted-by": "publisher",
      "first-page": "i185",
      "issue": "12",
      "journal-title": "Bioinformatics",
      "key": "511_CR83",
      "unstructured": "Leslie R, O’Donnell CJ, Johnson AD. GRASP: analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database. Bioinformatics. 2014;30(12):i185-194.",
      "volume": "30",
      "year": "2014"
    },
    {
      "DOI": "10.1093/nar/gky1120",
      "author": "A Buniello",
      "doi-asserted-by": "publisher",
      "first-page": "D1005",
      "issue": "D1",
      "journal-title": "Nucleic Acids Res",
      "key": "511_CR84",
      "unstructured": "Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Morales J, Mountjoy E, Sollis E, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005–12.",
      "volume": "47",
      "year": "2019"
    },
    {
      "DOI": "10.1186/s13059-014-0480-5",
      "author": "Y Fu",
      "doi-asserted-by": "publisher",
      "first-page": "480",
      "issue": "10",
      "journal-title": "Genome Biol",
      "key": "511_CR85",
      "unstructured": "Fu Y, Liu Z, Lou S, Bedford J, Mu XJ, Yip KY, Khurana E, Gerstein M. FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. Genome Biol. 2014;15(10):480.",
      "volume": "15",
      "year": "2014"
    },
    {
      "DOI": "10.1093/bioinformatics/btu703",
      "author": "D Quang",
      "doi-asserted-by": "publisher",
      "first-page": "761",
      "issue": "5",
      "journal-title": "Bioinformatics",
      "key": "511_CR86",
      "unstructured": "Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics. 2015;31(5):761–3.",
      "volume": "31",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41467-017-00443-5",
      "author": "S Balasubramanian",
      "doi-asserted-by": "publisher",
      "first-page": "382",
      "issue": "1",
      "journal-title": "Nat Commun",
      "key": "511_CR87",
      "unstructured": "Balasubramanian S, Fu Y, Pawashe M, McGillivray P, Jin M, Liu J, Karczewski KJ, MacArthur DG, Gerstein M. Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes. Nat Commun. 2017;8(1):382.",
      "volume": "8",
      "year": "2017"
    },
    {
      "DOI": "10.1093/nar/gky1016",
      "author": "P Rentzsch",
      "doi-asserted-by": "publisher",
      "first-page": "D886",
      "issue": "D1",
      "journal-title": "Nucleic Acids Res",
      "key": "511_CR88",
      "unstructured": "Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886–94.",
      "volume": "47",
      "year": "2019"
    },
    {
      "DOI": "10.1186/1479-7364-8-11",
      "author": "HA Shihab",
      "doi-asserted-by": "publisher",
      "first-page": "11",
      "journal-title": "Hum Genomics",
      "key": "511_CR89",
      "unstructured": "Shihab HA, Gough J, Mort M, Cooper DN, Day IN, Gaunt TR. Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. Hum Genomics. 2014;8:11.",
      "volume": "8",
      "year": "2014"
    },
    {
      "DOI": "10.1093/nar/gkx369",
      "author": "E Capriotti",
      "doi-asserted-by": "publisher",
      "first-page": "W247",
      "issue": "W1",
      "journal-title": "Nucleic Acids Res",
      "key": "511_CR90",
      "unstructured": "Capriotti E, Fariselli P. PhD-SNPg: a webserver and lightweight tool for scoring single nucleotide variants. Nucleic Acids Res. 2017;45(W1):W247–52.",
      "volume": "45",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ajhg.2016.08.016",
      "author": "NM Ioannidis",
      "doi-asserted-by": "publisher",
      "first-page": "877",
      "issue": "4",
      "journal-title": "Am J Hum Genet",
      "key": "511_CR91",
      "unstructured": "Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877–85.",
      "volume": "99",
      "year": "2016"
    },
    {
      "DOI": "10.1002/humu.22911",
      "author": "C Douville",
      "doi-asserted-by": "publisher",
      "first-page": "28",
      "issue": "1",
      "journal-title": "Hum Mutat",
      "key": "511_CR92",
      "unstructured": "Douville C, Masica DL, Stenson PD, Cooper DN, Gygax DM, Kim R, Ryan M, Karchin R. Assessing the pathogenicity of insertion and deletion variants with the variant effect scoring tool (VEST-Indel). Hum Mutat. 2016;37(1):28–35.",
      "volume": "37",
      "year": "2016"
    },
    {
      "DOI": "10.1200/CCI.19.00132",
      "author": "KA Pagel",
      "doi-asserted-by": "publisher",
      "first-page": "310",
      "journal-title": "JCO Clin Cancer Inform",
      "key": "511_CR93",
      "unstructured": "Pagel KA, Kim R, Moad K, Busby B, Zheng L, Tokheim C, Ryan M, Karchin R. Integrated informatics analysis of cancer-related variants. JCO Clin Cancer Inform. 2020;4:310–7.",
      "volume": "4",
      "year": "2020"
    },
    {
      "DOI": "10.1101/gr.239244.118",
      "author": "A Mayakonda",
      "doi-asserted-by": "publisher",
      "first-page": "1747",
      "issue": "11",
      "journal-title": "Genome Res",
      "key": "511_CR94",
      "unstructured": "Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.",
      "volume": "28",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.cell.2018.03.035",
      "author": "F Sanchez-Vega",
      "doi-asserted-by": "publisher",
      "first-page": "321",
      "issue": "2",
      "journal-title": "Cell",
      "key": "511_CR95",
      "unstructured": "Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321-337 e310.",
      "volume": "173",
      "year": "2018"
    },
    {
      "DOI": "10.1038/ng.2702",
      "author": "SA Roberts",
      "doi-asserted-by": "publisher",
      "first-page": "970",
      "issue": "9",
      "journal-title": "Nat Genet",
      "key": "511_CR96",
      "unstructured": "Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970–6.",
      "volume": "45",
      "year": "2013"
    }
  ],
  "reference-count": 96,
  "references-count": 96,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00511-6"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "17"
}